Originally published as JCO Early Release 10.1200/JCO.2007.11.5451 on January 7 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Partridge, A. H. Articles by Asnis-Alibozek, A. PubMed PubMed Citation Articles by Partridge, A. H. Articles by Asnis-Alibozek, A. Related Articles Related Editorial

Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer

Ann H. Partridge, Andrea LaFountain, Erica Mayer, Brooke S. Taylor, Eric Winer, Aviva Asnis-Alibozek

From the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and AstraZeneca Pharmaceuticals, Wilmington, DE

Corresponding author: Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: ahpartridge{at}partners.org

Purpose: Previous research evaluating adherence to tamoxifen therapy among women with early-stage breast cancer has revealed adherence estimates ranging from 25% to 96%. No previous studies have focused on adherence to adjuvant aromatase inhibitors.

Methods: We used longitudinal claims data from three large commercial health programs to estimate adherence with anastrozole therapy among women with early-stage breast cancer. Adherence was defined as the proportion of days that patients had medication available over the observation period (ie, days covered); women with fewer than 80% of days covered were defined as nonadherent.

Results: More than 12,000 women in the databases were found to have new anastrozole prescription claims during the period of study: 1,498 women were classified as having early-stage disease in one commercial health program (Plan A) data set, 1,899 women in another program (Plan B) data set, and 8,994 women in MarketScan, a commercial data set made up of several health programs. Mean adherence over the first 12 months of therapy ranged from 82% to 88% in the three data sets. Between 19% and 28% of women had fewer than 80% of days covered. For women with 36 months of continuous eligibility, the mean adherence decreased each year, ranging from 78% to 86% in year 1 to 62% to 79% in year 3 within the three data sets.

Conclusion: A substantial proportion of women with early-stage breast cancer may be suboptimally adherent to adjuvant anastrozole therapy. Future research should focus on the identification of patients at risk for nonadherence with oral hormonal therapy for breast cancer and the development of interventions to improve adherence.

published online ahead of print at www.jco.org on January 7, 2008.

Presented as a poster at the 2006 San Antonio Breast Cancer Symposium, December 14-17, 2006, San Antonio, TX. An associated abstract was published in Breast Cancer Res Treat 100:S186, 2006 (suppl 1; abstr 4044).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Editorial

• Moving Research From Bench to Bedside to Community: There Is Still More to Do
  Katherine L. Kahn
  JCO 2008 26: 523-526 [Full Text]

This article has been cited by other articles:

				D. L. Hershman Getting a Grip on Aromatase Inhibitor-Associated Arthralgias J. Clin. Oncol., July 1, 2008; 26(19): 3120 - 3121. [Full Text] [PDF]

				K. L. Kahn Moving Research From Bench to Bedside to Community: There Is Still More to Do J. Clin. Oncol., February 1, 2008; 26(4): 523 - 526. [Full Text] [PDF]